期刊
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
卷 5, 期 1, 页码 30-43出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040622313511286
关键词
anterior chamber; glaucoma; ocular hypertension; ophthalmic solutions; optic nerve diseases; trabecular meshwork; vision disorders
资金
- Research to Prevent Blindness, New York, USA
Lowering intraocular pressure (IOP) is the only proven therapeutic intervention for glaucomatous optic neuropathy. Despite advances in laser and microsurgical techniques, medical IOP reduction remains the first-line treatment option for the majority of patients with open-angle glaucoma. Prostaglandin analogs are the most efficacious topical agents and carry a remarkable safety profile. Topical beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors are often employed as adjunctive agents for further IOP control. Newer preserved and nonpreserved formulations are available and appear to be less toxic to the ocular surface. Oral carbonic anhydrase inhibitors, miotic agents, and hyperosmotics are infrequently used due to a host of potentially serious adverse events. Medical therapies on the horizon include rho-kinase inhibitors, neuroprotective interventions, and gene therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据